Clinical Trial Update: Trial of Atezolizumab and Bevacizumab With SRF388 or Placebo in Patients With Hepatocellular Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating atezolizumab and bevacizumab with SRF388 or placebo in hepatocellular carcinoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Atezolizumab (atezolizumab)
• Bevacizumab (bevacizumab)
• SRF388

Snippet

Sponsor: Coherus Oncology, Inc. | Conditions: Hepatocellular Carcinoma | Phase 2 | Status: COMPLETED